Condition
Autoimmune Diseases of the Nervous System
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
14 shownMusic-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility StudyNCT07759115 · 2026-08-10
RECRUITINGBiomarkers in Autoimmune Disease of Nervous SystemNCT06502015 · 2024-07-31
RECRUITINGNon-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSNCT05834855 · 2023-04-01
RECRUITINGSafety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemNCT04561557 · 2020-09-22
RECRUITINGIDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDEDUkulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility StudyNCT05792176 · 2023-03-27
COMPLETEDAcceptability of Exoskeleton Assisted Walking for Persons With Mobility Issues Due to Multiple SclerosisNCT04786821 · 2022-06-23
COMPLETEDAerobic Exercise for Remyelination in Multiple SclerosisNCT04539002 · 2021-04-29
COMPLETEDHumoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or NatalizumabNCT04837651 · 2021-03-02
COMPLETEDPower Training in Older Multiple Sclerosis PatientsNCT04762342 · 2020-12-07
UNKNOWNSafety and Efficacy of Melatonin in Patients With Multiple Progressive Primary SclerosisNCT03540485 · 2019-11-29
TERMINATEDStudy to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple SclerosisNCT01453764 · 2016-04-01
WITHDRAWNStudy of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple SclerosisNCT01684761 · 2012-08-01
COMPLETEDAutologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple SclerosisNCT01056471 · 2010-01-01
COMPLETEDCommon interventions
Music ListeningBEHAVIORAL2Music Training InterventionBEHAVIORAL2Aerobic exerciseBEHAVIORAL1Autologous mesenchymal stem cells from adipose tissue.OTHER1biomaker levelsDIAGNOSTIC_TEST1CT103A cellsBIOLOGICAL1CyclophosphamideDRUG1Cyclophosphamide and fludarabineDRUG1Education Group ControlBEHAVIORAL1Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testDEVICE1FludarabineDRUG1Harvesting and Implantation of SVFPROCEDURE1IDP-023DRUG1Interleukin-2DRUG1MelatoninDRUG1MesnaDRUG1OcrelizumabDRUG1Phoenix Exoskeleton suitDEVICE1PlaceboBIOLOGICAL1PlaceboOTHER1Power trainingOTHER1RituximabDRUG1Standard Exercise TrainingBEHAVIORAL1T-Detect COVID T-cell blood testDEVICE1TcelnaBIOLOGICAL1
Leading sponsors
Tongji Hospital
2
University of Texas at Austin
2
Ageless Regenerative Institute
1
Amsterdam UMC, location VUmc
1
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
1
Dragonfly Research, LLC
1
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
1
Indapta Therapeutics, INC.
1
Opexa Therapeutics, Inc.
1
Oregon Health and Science University
1
Sheffield Teaching Hospitals NHS Foundation Trust
1
University of Aarhus
1
Trial status mix
COMPLETED6
RECRUITING4
SUSPENDED1
TERMINATED1
UNKNOWN1
WITHDRAWN1
Phase mix
NA6
PHASE13
PHASE23
EARLY_PHASE11
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.